HURA - TuHURA Biosciences, Inc./NV

QQQ $ 629.78 $ -3.11 (-0.49 %)

DIA $ 472.70 $ -2.66 (-0.56 %)

SPY $ 681.88 $ -2.29 (-0.33 %)

TLT $ 89.68 $ 0.07 (0.08 %)

GLD $ 366.72 $ 0.05 (0.01 %)

Previous Close

$ 2.54

Open

$ 2.52

Bid

$ 2.45 x 258

Ask

$ 2.62 x 30

Day's Range

$ 2.46 - $ 2.59

52 Week Range

$ 1.80 - $ 7.20

Volume

153,455

Average Volume

Market Cap

4.26M

Beta (5Y Monthly)

$ 0.91

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-14-2025	06-30-2025	10-Q
2	05-15-2025	03-31-2025	10-Q
3	03-31-2025	12-31-2024	10-K
4	11-14-2024	09-30-2024	10-Q
5	10-07-2024	06-30-2024	10-K
6	05-14-2024	03-31-2024	10-Q
7	02-14-2024	12-31-2023	10-Q
8	11-13-2023	09-30-2023	10-Q
9	09-18-2023	06-30-2023	10-K
10	05-11-2023	03-31-2023	10-Q
11	02-14-2023	12-31-2022	10-Q
12	11-09-2022	09-30-2022	10-Q
13	09-27-2022	06-30-2022	10-K
14	05-13-2022	03-31-2022	10-Q
15	02-11-2022	12-31-2021	10-Q
16	11-15-2021	09-30-2021	10-Q
17	09-28-2021	06-30-2021	10-K
18	05-13-2021	03-31-2021	10-Q
19	02-12-2021	12-31-2020	10-Q
20	11-12-2020	09-30-2020	10-Q
21	09-18-2020	06-30-2020	10-K
22	05-13-2020	03-31-2020	10-Q
23	02-13-2020	12-31-2019	10-Q
24	11-13-2019	09-30-2019	10-Q
25	09-09-2019	06-30-2019	10-K
26	05-14-2019	03-31-2019	10-Q
27	02-11-2019	12-31-2018	10-Q
28	11-13-2018	09-30-2018	10-Q
29	09-24-2018	06-30-2018	10-K
30	05-15-2018	03-31-2018	10-Q
31	02-14-2018	12-31-2017	10-Q
32	11-09-2017	09-30-2017	10-Q
33	09-27-2017	06-30-2017	10-K
34	05-12-2017	03-31-2017	10-Q
35	02-10-2017	12-31-2016	10-Q
36	11-10-2016	09-30-2016	10-Q
37	09-13-2016	06-30-2016	10-K
38	05-12-2016	03-31-2016	10-Q
39	02-12-2016	12-31-2015	10-Q
40	11-16-2015	09-30-2015	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

TuHURA Biosciences Files For Mixed Shelf O...
11/03/2025 22:43:47

- SEC Filing

TuHURA Biosciences To Present First Eviden...
11/03/2025 14:15:07

Oral presentation highlights the first time it's been demonstrated that the DOR is expressed on tumor-associated MDSCs, and...

TuHURA Biosciences Q2 EPS $(0.21) Misses $...
08/14/2025 20:42:57

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of ...

12 Health Care Stocks Moving In Wednesday'...
08/13/2025 17:06:22

Florida Rep. Laurel Lee Sold Up to $265K W...
08/12/2025 15:00:33

12 Health Care Stocks Moving In Monday's I...
08/11/2025 17:06:46

TuHURA Biosciences Added To Russell 3000 I...
07/01/2025 12:51:17

TuHURA Biosciences Initiates Phase 3 Accel...
06/24/2025 12:01:47

12 Health Care Stocks Moving In Monday's A...
06/23/2025 21:06:48

TuHURA Biosciences And Kineta Receive Stoc...
06/23/2025 21:04:08

FDA Removes Manufacturing-Related Partial ...
06/09/2025 12:11:11

Company anticipates initiating its Phase 3 accelerated approval trial of IFx-Hu2.0 as adjunctive therapy with Keytruda® (pembro...

TuHURA Biosciences Presents IFx-Hu2.0 Tria...
06/02/2025 12:14:33

Phase 3 IFx-Hu2.0 trial as an adjunctive therapy with Keytruda® (pembrolizumab) in checkpoint inhibitor (CPI)-naïve patients wi...

HC Wainwright & Co. Reiterates Buy on TuHU...
05/16/2025 11:12:08

HC Wainwright & Co. analyst Robert Burns reiterates TuHURA Biosciences (NASDAQ:HURA) with a Buy and maintains $12 price ...

TuHURA Biosciences Q1 EPS $(0.15) Misses $...
05/15/2025 20:37:12

TuHURA Biosciences (NASDAQ:HURA) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of ...

TuHURA Biosciences Initiates Phase 1b/2a S...
05/05/2025 12:05:33

Phase 1b/2a trial designed to evaluate the safety and feasibility of IFx-Hu2.0 in combination with Keytruda® when administered ...

TuHURA Biosciences And Kineta Present Upda...
04/28/2025 12:09:23

Kineta presents updated clinical data from VISTA-101 trial of KVA12123, demonstrating >90% VISTA receptor occupancy at 1,000mg

HC Wainwright & Co. Maintains Buy on TuHUR...
04/03/2025 11:47:40

HC Wainwright & Co. analyst Robert Burns maintains TuHURA Biosciences (NASDAQ:HURA) with a Buy and lowers the price targ...

TuHURA Biosciences FY24 EPS ($1.21) Up Fro...
04/01/2025 12:13:56

12-health-care-stocks-moving-in-wednesdays-intraday-session

12 Health Care Stocks Moving In Wednesday'...
03/19/2025 17:06:05

12-health-care-stocks-moving-in-tuesdays-intraday-session

12 Health Care Stocks Moving In Tuesday's ...
03/18/2025 17:05:46